From Biohacking to Healthcare- the growing pain of the Longevity Industry Shownotes the BioRevolution podcast episode 48 For most of human history, “living longer” mainly meant not dying early but this has changed drastically with significantly increased life expectancy in the 20th century. This raises a new question: how can we live longer, individually and as a society, without simply shifting the burden into more years lived with chronic disease? Researchers are increasingly reframing the problem away from purely disease-by-disease fixes and toward the underlying biology of ageing that contributes to multiple conditions, such as cancer, cardiovascular, neurodegenerative, and metabolic disease. While the field is only beginning to untangle the complex, and likely multifactorial process of aging, a fledgling longevity industry has emerged around various hypotheses of aging mechanisms. The longevity industry spans therapeutics that target ageing-linked mechanisms, biomarkers and “clocks” that aim to measure biological ageing, and delivery models (clinics, digital platforms, consulting) that package measurement and interventions into services.

In episode 48 of the BioRevolution podcast, we talk to Niko Hems, Growth Lead of Berlin-based longevity company YEARS and longevity writer and podcaster. Find Niko here: https://www.linkedin.com/in/niko-hems/ Find Niko’s “Beyond the Hype” course here: https://beyondthehype.kit.com/niko Find Niko’s podcast “Return on Health” with Miguel Medina here: https://open.spotify.com/show/3UmkL9XmmCGIs3jrxSV9CY?si=a74386952a2940f8 Find YEARS here: https://www.years.co/de

Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast.

Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow

Sources

1. https://ourworldindata.org/data-insights/global-average-life-expectancy-has-more-than-doubled-since-1900
2. https://www.nature.com/articles/s43587-024-00702-3
3. https://pubmed.ncbi.nlm.nih.gov/39418098/
4. https://pubmed.ncbi.nlm.nih.gov/36599349/
5. https://pubmed.ncbi.nlm.nih.gov/37118377/
6. https://pharmaphorum.com/news/billionaire-backed-rejuvenation-start-up-altos-labs-launches-operations
7. https://blog.newlimit.com/p/newlimit-raises-130-million-series
8. https://pulse24.ai/news/2025/8/22/20/ai-boosts-cell-rejuvenation
9. https://www.biopharmatrend.com/news/fda-greenlights-first-human-trial-of-epigenetic-rejuvenation-therapy-for-vision-loss-1483/
10. https://shiftbioscience.com/shift-bioscience-raises-16m-to-advance-ai-virtual-cell-platform-for-cell-rejuvenation/
11. https://clock.bio/
12. https://pubmed.ncbi.nlm.nih.gov/40563501/
13. https://www.pharmiweb.com/press-release/2025-09-17/rubedo-life-sciences-announces-us-fda-clearance-of-ind-for-selective-gpx4-modulating-lead-drug-can
14. https://longevity.technology/news/senisca-raises-3-7-million-for-rapid-development-of-senotherapeutic-platform/
15. https://dogagingproject.org/
16. https://www.nature.com/articles/s41587-025-02932-1
17. https://link.springer.com/rwe/10.1007/978-3-030-22009-9_400
18. https://www.businesswire.com/news/home/20251216261885/en/Aeovian-Pharmaceuticals-Raises-%2455-Million-to-Advance-First-in-Class-Selective-mTORC1-Inhibitor-for-Tuberous-Sclerosis-Complex-Related-Epilepsy
19. https://pubmed.ncbi.nlm.nih.gov/34425083/
20. https://www.biospace.com/press-releases/novo-nordisk-a-s-evoke-phase-3-trials-did-not-demonstrate-a-statistically-significant-reduction-in-alzheimers-disease-progression
21. https://pubmed.ncbi.nlm.nih.gov/37179335/
22. https://www.businesswire.com/news/home/20250111808660/en/Immunis-Closes-%2425-Million-Series-A-1-Financing-Round
23. hervolutiontx.com/news/dark-genome-biotech-hervolution-therapeutics-announces-11.7m-series-a-to-advance-treatments-for-cancer-and-diseases-of-aging/
24. https://www.pretzeltx.com/pretzel-therapeutics-initiates-phase-1-clinical-study-evaluating-px578-lead-therapeutic-in-its-bioenergetics-restoration-franchise/
25. https://pubmed.ncbi.nlm.nih.gov/35498045/
26. https://pubmed.ncbi.nlm.nih.gov/24138928/
27. https://www.theguardian.com/science/2024/dec/26/scientists-explore-longevity-drugs-for-dogs-that-could-also-extend-human-life
28. https://www.geneticsandsociety.org/article/embryo-models-challenge-legal-ethical-and-biological-concepts
29. https://www.repairbiotechnologies.com/repair-biotechnologies-receives-orphan-drug-designation-from-the-fda-for-the-treatment-of-homozygous-familial-hypercholesterolemia/
30. https://a16z.com/announcement/function-health-series-b/
31. https://techcrunch.com/2025/08/13/tony-robbins-and-peter-diamandis-longevity-company-fountain-life-raises-18m/
32. https://years.co/
33. https://pmc.ncbi.nlm.nih.gov/articles/PMC12606959/